#Akba

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) Akebia Therapeutics (Nasdaq: AKBA) announced that the first patient has been dosed in a Phase 2 randomized, double-blind, placebo-controlled study of oral once-daily praliciguat for biopsy-confirmed focal segmental glomerulosclerosis (FSGS).The study will randomize ~60 adults on maximally tolerated ACEi/ARB therapy 1:1 to praliciguat or placebo for a 24-week double-blind period followed by a 24-week open-label extension. The primary endpoint is change in urine protein-to-creatinine ratio (UPCR) at Week 24; a key secondary endpoint is partial remission defined as 40% UPCR reduction and UPCR <1.5 g/g.

2 months ago

#AKBA Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

www.stocktitan.net/news/AKBA/akebia-therape...

0 0 0 0

3 months ago

#AKBA Akebia Announces Establishment of Rare Kidney Disease Pipeline

www.stocktitan.net/news/AKBA/akebia-announc...

0 0 0 0

4 months ago

Charts of the Day - small-cap stocks forming dark cloud cover candlestick signal, Tue Oct 28th - #AKBA #PMN - More: crystalequityresearch.com/charts-of-th... - #smallcap

0 0 0 0

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney

4 months ago

#AKBA Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

www.stocktitan.net/news/AKBA/akebia-therape...

0 0 0 0

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025 Akebia Therapeutics (Nasdaq: AKBA) will present five scientific items at ASN Kidney Week 2025 in Houston, Nov 5-9, 2025, and staff the company booth #903.Highlights include an oral win‑odds analysis of all‑cause mortality and hospitalization from the global Phase 3 INNO2VATE trials (presenter: Glenn M. Chertow, MD) on Nov 6, 2025, 4:30–6:00 PM CT, Room 351D, and four Akebia‑supported posters on Nov 6–7 covering model‑based starting dose recommendations for Vafseo (vadadustat), dosing consistency vs darbepoetin, and two ongoing real‑world randomized studies (VOICE and VOCAL) assessing three‑times‑weekly vadadustat in dialysis patients. Vafseo is approved in the U.S. for anemia in adults on dialysis ≥3 months.

4 months ago

#AKBA Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025

www.stocktitan.net/news/AKBA/akebia-therape...

0 0 0 0

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics Akebia Therapeutics (Nasdaq: AKBA) and Innovative Renal Care (IRC) announced the nationwide availability of Vafseo® (vadadustat) across IRC's network of over 230 dialysis centers in 28 states and Washington, D.C. The treatment is now accessible to eligible patients among IRC's 16,000+ patient base.Vafseo, FDA-approved in March 2024 for treating anemia due to chronic kidney disease in adults on dialysis for at least three months, became commercially available in January 2025. The drug is now accessible to over 55,000 patients through dialysis provider protocols, with expected expansion to reach 275,000 patients by Q4 2025.

6 months ago

#AKBA Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

www.stocktitan.net/news/AKBA/akebia-therape...

0 0 0 0

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Akebia Therapeutics (Nasdaq: AKBA) reported strong Q2 2025 financial results, highlighted by total net product revenues of $60.5 million. The company's newly launched anemia drug Vafseo® (vadadustat) generated $13.3 million in net product revenue, with prescription demand growing 55% over Q1. Auryxia® sales contributed $47.2 million.Key developments include DaVita's operational pilot of Vafseo across 100+ dialysis clinics starting August 2025, completed enrollment in the VOICE trial with 2,116 patients, and initiation of the VOCAL trial for three-times-weekly dosing evaluation. The company achieved profitability with a net income of $0.2 million, compared to an $8.6 million loss in Q2 2024, and maintained a strong cash position of $137.3 million.

7 months ago

#AKBA Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/AKBA/akebia-therape...

0 0 0 0

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization Akebia Therapeutics (Nasdaq: AKBA) has launched the VOCAL trial, a post-marketing study for its FDA-approved anemia treatment Vafseo® (vadadustat). The study, conducted in partnership with DaVita clinics, will evaluate the benefits of three-times-weekly Vafseo dosing compared to standard erythropoiesis-stimulating agents (ESA) in dialysis patients.The trial will enroll approximately 350 patients across 18 DaVita hemodialysis clinics for up to 33 weeks. The study includes a sub-study of 28 patients to analyze red blood cell quality. Primary endpoints focus on hemoglobin changes, while secondary endpoints include serious adverse events, target hemoglobin achievement, and RBC transfusion requirements.

7 months ago

#AKBA Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

www.stocktitan.net/news/AKBA/akebia-initiat...

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

8 months ago

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - Yahoo Akebia Therapeutics (AKBA) Grants Stock Options to New Employees Yahoo

Click Subscribe #AkebiaTherapeutics #AKBA #StockOptions #Biotechnology #EmployeeBenefits

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

9 months ago

Small-cap stocks overbought with declining relative strength, Wed Jun 11th - #NEGG #LIMN #KYTX #FTEK #EYEN #CMPX #BIRD #AKBA #YEXT #SANA #THRD #ULBI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

New Clinical Trial Results Reveal Critical U.S. Patient Data for Akebia's Kidney Disease Treatment Latest analysis compares U.S. vs global outcomes for vadadustat in treating CKD-related anemia. Key safety and efficacy metrics revealed. See detailed findings.

9 months ago

#AKBA Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

www.stocktitan.net/news/AKBA/vadadustat-u-s...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

9 months ago

Most searched small-cap stocks, Mon Jun 2nd - #NVTS #UUUU #ZJUN #VLRS #LYRA #NIVF #TRMD #SPCE #SEDG #RIOT #RIG #RGTI #MAG #LEU #HL #EVH #BTCS #BMGL #APLD #AKBA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

1 0 0 0

Akebia Unveils Critical Cardiovascular Safety Analysis for Vadadustat in Dialysis Patients at ERA Congress New cardiovascular safety analysis of Vadadustat in dialysis patients headlines three clinical presentations at ERA 2025. See latest real-world data insights.

9 months ago

#AKBA Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

www.stocktitan.net/news/AKBA/akebia-therape...

0 0 0 0

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Akebia Therapeutics (AKBA) reported strong Q1 2025 financial results, highlighted by the successful U.S. launch of Vafseo® (vadadustat) for anemia in dialysis patients. The company generated $12.0 million in Vafseo net product revenues and total net product revenues of $55.8 million. Over 640 prescribers wrote prescriptions for Vafseo, with each averaging nearly 12 prescriptions. Auryxia® revenues reached $43.8 million. The company strengthened its financial position through a $50 million public offering, ending Q1 with $113.4 million in cash. Akebia reported a net income of $6.1 million, compared to a net loss of $18.0 million in Q1 2024. The company plans to initiate the VALOR Phase 3 trial for vadadustat in non-dialysis CKD patients in H2 2025.

10 months ago

#AKBA Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/AKBA/akebia-therape...

0 0 0 0

Major Win for Akebia: EMA Committee Recommends Novel Dual-Action Kidney Disease Treatment Novel oral therapy targets both phosphorous and iron deficiency in CKD patients. European approval decision expected within two months. Full market implications inside.

11 months ago

#AKBA Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

www.stocktitan.net/news/AKBA/akebia-therape...

0 0 0 0

Breakthrough Kidney Disease Treatment Data: Akebia's Vadadustat Shows Promising Results Latest Vadadustat research reveals cardiovascular safety data and age-based efficacy analysis in dialysis patients. Key findings to be presented at NKF Spring Meeting.

11 months ago

#AKBA Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

www.stocktitan.net/news/AKBA/akebia-therape...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

11 months ago

Most searched small-cap stocks, Thu Mar 20th - #NGD #IQ #BTE #RIG #AKBA #CLSK #FSM #RIOT #APLD #CORZ #ASO #RR #CTM #FRO #LX #NVTS #PSTV #QBTS #QUBT #RGTI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Akebia Therapeutics Raises $50M: Major Stock Offering Priced at $2.00 Per Share Biotech firm secures $50M through 25M share offering, with option for additional 3.75M shares. Led by Leerink Partners and Piper Sandler, closing expected March 2025.

11 months ago

#AKBA Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

www.stocktitan.net/news/AKBA/akebia-therape...

0 0 0 0

Akebia Therapeutics Unveils Major Public Offering: Key Details for Investors Akebia Therapeutics initiates underwritten public offering with 15% additional share option. Leerink Partners and Piper Sandler lead the strategic capital raise through SEC-registered shares.

11 months ago

#AKBA Akebia Therapeutics Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/AKBA/akebia-therape...

0 0 0 0

InsiderFinance

@insiderfinance.com

1 year ago

🚨 Institutions #optionsvolume surge detected!

Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #MATV 400.0x
2. #AKBA 80.0x
3. #HBM 40.0x
4. #TBCH 9.6x
5. #ULTA 6.4x

#OptionFlow #OptionsTrading #Trading

0 0 0 0

Akebia's New Drug Vafseo Captures Entire US Dialysis Market, Projects $11M Q1 Revenue Akebia's Vafseo secures 100% US dialysis coverage with 500+ prescribers. Q4 revenue $46.5M, strong launch metrics signal growth potential in kidney disease treatment market.

1 year ago

#AKBA Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

www.stocktitan.net/news/AKBA/akebia-therape...

0 0 0 0

Akebia's Vafseo Launch Secures Coverage for Nearly All U.S. Dialysis Patients, 99% of Doctors Show Interest Akebia Therapeutics achieves major milestone as Vafseo, its CKD anemia treatment, secures nationwide dialysis coverage. Strong physician support signals promising market adoption.

1 year ago

#AKBA Akebia Therapeutics Announces Multiple Positive Business Updates

www.stocktitan.net/news/AKBA/akebia-therape...

0 0 0 0

1 year ago

#AKBA Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

www.stocktitan.net/news/AKBA/akebia-therape...

0 0 0 0